Approved drugs and natural products at clinical stages for treating Alzheimer’s disease

IF 4 2区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Chinese Journal of Natural Medicines Pub Date : 2024-08-01 DOI:10.1016/S1875-5364(24)60606-0

Yajing MA , Sufang LIU , Qingfeng ZHOU , Zhonghua LI , Zhijian ZHANG , Bin YU

{"title":"Approved drugs and natural products at clinical stages for treating Alzheimer’s disease","authors":"Yajing MA , Sufang LIU , Qingfeng ZHOU , Zhonghua LI , Zhijian ZHANG , Bin YU","doi":"10.1016/S1875-5364(24)60606-0","DOIUrl":null,"url":null,"abstract":"<div><p>Alzheimer’s disease (AD) remains the foremost cause of dementia and represents a significant unmet healthcare need globally. The complex pathogenesis of AD, characterized by various pathological and physiological events, has historically challenged the development of anti-AD drugs. However, recent breakthroughs in AD drug development, including the approvals of aducanumab, lecanemab, and sodium oligomannate (GV-971), have ended a nearly two-decade hiatus in the introduction of new AD drugs. These developments have addressed long-standing challenges in AD drug development, marking a substantial shift in the therapeutic landscape of AD. Moreover, natural products (NPs) have shown promise in AD drug research, with several currently under clinical investigation. Their distinct properties and mechanisms of action offer new avenues to complement and enhance existing AD treatment approaches. This review article aims to provide an overview of the recent advancements and prospects in AD therapeutics, focusing on both NPs and approved drugs.</p></div>","PeriodicalId":10002,"journal":{"name":"Chinese Journal of Natural Medicines","volume":"22 8","pages":"Pages 699-710"},"PeriodicalIF":4.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Natural Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875536424606060","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer’s disease (AD) remains the foremost cause of dementia and represents a significant unmet healthcare need globally. The complex pathogenesis of AD, characterized by various pathological and physiological events, has historically challenged the development of anti-AD drugs. However, recent breakthroughs in AD drug development, including the approvals of aducanumab, lecanemab, and sodium oligomannate (GV-971), have ended a nearly two-decade hiatus in the introduction of new AD drugs. These developments have addressed long-standing challenges in AD drug development, marking a substantial shift in the therapeutic landscape of AD. Moreover, natural products (NPs) have shown promise in AD drug research, with several currently under clinical investigation. Their distinct properties and mechanisms of action offer new avenues to complement and enhance existing AD treatment approaches. This review article aims to provide an overview of the recent advancements and prospects in AD therapeutics, focusing on both NPs and approved drugs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

已获批准的治疗阿尔茨海默病的药物和处于临床阶段的天然产品

阿尔茨海默病（AD）仍然是痴呆症的首要病因，也是全球尚未满足的重大医疗需求。阿兹海默症的发病机制复杂，以各种病理和生理事件为特征，因此抗阿兹海默症药物的开发一直面临挑战。然而，最近在抗注意力缺失症药物开发方面取得的突破，包括阿杜单抗、利卡尼单抗和寡甘氨酸钠（GV-971）的获批，结束了近二十年来注意力缺失症新药迟迟未能问世的局面。这些研发成果解决了 AD 药物研发中长期存在的难题，标志着 AD 治疗领域发生了重大转变。此外，天然产物（NPs）在注意力缺失症药物研究中也大有可为，目前有几种天然产物正在进行临床研究。它们与众不同的特性和作用机制为补充和加强现有的AD治疗方法提供了新的途径。这篇综述文章旨在概述AD疗法的最新进展和前景，重点关注NPs和已获批准的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chinese Journal of Natural Medicines INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY

CiteScore

7.50

自引率

4.30%

发文量

2235

期刊介绍： The Chinese Journal of Natural Medicines (CJNM), founded and sponsored in May 2003 by China Pharmaceutical University and the Chinese Pharmaceutical Association, is devoted to communication among pharmaceutical and medical scientists interested in the advancement of Traditional Chinese Medicines (TCM). CJNM publishes articles relating to a broad spectrum of bioactive natural products, leading compounds and medicines derived from Traditional Chinese Medicines (TCM). Topics covered by the journal are: Resources of Traditional Chinese Medicines; Interaction and complexity of prescription; Natural Products Chemistry (including structure modification, semi-and total synthesis, bio-transformation); Pharmacology of natural products and prescription (including pharmacokinetics and toxicology); Pharmaceutics and Analytical Methods of natural products.